5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia

• Status: Completed
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study,investigators will recruit 100 DSM-Ⅴdefined EOS Han patients, older than 7 years old and onset of illness before 17 years old, and all EOS patients will receive a 8-week systematic olanzepine titration treatment and a battery of assessments of treatment effect and safety. Blood olanzepine plasma concentration will be tested regularly and genotyping of 8 polymorphisms of 5-HTR2A, DRD2 and COMT genes will be conducted by Polymerase Chain Reaction （PCR）, Restriction Fragment Length Polymorphism (RFLP) and TaqMan probes genotyping technology. The aim of the study is to explore the predictive factors on olanzepine treatment response in EOS, which can guide the individualized treatment and improve the cure rate of EOS in clinical setting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kunming Medical University
• Collaborator: National Natural Science Foundation of China
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• above 7 years old,

• age of onset ≤17 years old,

• Han or other nationality, male or female,

• in line with the diagnostic DSM-V criteria for schizophrenia, and

• negative and positive symptom scale (Positive and Negative Syndrome Scale, PANSS) score ≥70 points;

• patients are in the condition of first-episode, or relapse.

Exclusion Criteria:

• IQ <70,

• current or previous history of traumatic brain injury,

• psychoactive substance use,

• personality disorders,

• obvious abnormalities on physical and laboratory examination,

• previous allergy or olanzapine had significant adverse reactions.